Cidara Therapeutics
CDTX

$11.94

5.2%

Market Cap: $84M

About: Cidara Therapeutics Inc is developing immunotherapeutics designed to help improve the standard of care for patients facing serious diseases. The Company's portfolio comprises new approaches aimed at transforming existing treatment and prevention paradigms, including DFCs from its proprietary Cloudbreak platform targeting oncologic, viral and autoimmune diseases.

Employees: 73

Healthcare Biological Products, Except Diagnostic Substances

0

Funds holding %

of 6,710 funds

–

Analysts bullish %

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

6.7% more ownership

Funds ownership: 24.36% [Q1] → 31.06% (+6.7%) [Q2]

0% more funds holding in top 10

Funds holding in top 10: 1 [Q1] → 1 (+0) [Q2]

17% less capital invested

Capital invested by funds: $20.3M [Q1] → $16.9M (-$3.38M) [Q2]

48% less funds holding

Funds holding: 50 [Q1] → 26 (-24) [Q2]

83% less first-time investments, than exits

New positions opened: 5 | Existing positions closed: 29

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 19

See Fund Rankings

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$24

101%

upside

Avg. target

$25

105%

upside

High target

$25

109%

upside

2 analyst ratings

2 positive

100%

0 neutral

0%

0 negative

0%

HC Wainwright & Co. Ed Arce 39% 1-year accuracy 52 / 132 met price target	101%upside $24	Buy Upgraded	14 Aug 2024
Needham Joseph Stringer 65% 1-year accuracy 85 / 131 met price target	109%upside $25	Buy Reiterated	14 Aug 2024

See Analyst Rankings

Financial journalist opinion

Based on 3 articles about CDTX published over the past 30 days

Cidara Therapeutics Restructures Workforce to Focus on Planned Clinical Development of CD388

SAN DIEGO, Sept. 12, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, today announced a reduction in its workforce to focus on the clinical development of CD388, the Company's novel DFC candidate for influenza A and B. The planned reduction impacts approximately 30% of the Cidara workforce.

Cidara Therapeutics Restructures Workforce to Focus on Planned Clinical Development of CD388

Cidara to Present at the H.C. Wainwright 26th Annual Global Investment Conference

SAN DIEGO, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX) (the Company), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, today announced that Jeffrey Stein, Ph.D., President and Chief Executive Officer, will present at the H.C. Wainwright 26th Annual Global Investment Conference.

Cidara to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Cidara Therapeutics Announces Appointment of Jim Beitel as Chief Business Officer

Appointment adds biotech veteran with over two decades of business development, strategy, and operational experience to Cidara's management team Appointment adds biotech veteran with over two decades of business development, strategy, and operational experience to Cidara's management team

Cidara Therapeutics Announces Appointment of Jim Beitel as Chief Business Officer

Cidara Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results

SAN DIEGO, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX) (the Company), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, today reported financial results for the second quarter ended June 30, 2024, and provided an update on its corporate activities and product pipeline.

Cidara Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results

Cidara Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, July 03, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, today announced that the Compensation Committee of its Board of Directors granted Corrina Pavetto, a new employee, a non-qualified stock option award and restricted stock units (RSUs) for an aggregate of 10,275 shares of its common stock, pursuant to the Cidara Therapeutics, Inc. 2020 Inducement Incentive Plan, with a grant date of June 28, 2024. The stock option has an exercise price of $11.94 per share, which is equal to the closing price of Cidara's common stock on the grant date. The shares subject to the option will vest over four years, with 25% of the shares vesting on the one-year anniversary of the vesting commencement date and the balance of the shares vesting in a series of 36 successive equal monthly installments thereafter. All RSUs vest in four equal annual installments, with 1/4 vesting on each of the first, second, third and fourth anniversaries of the Quarterly Vesting Date that occurs during the calendar quarter that includes the Date of Grant. Quarterly Vesting Date means March 10, June 10, September 10 or December 10. The awards are subject to the award holder's continuous service through each vesting date and to the terms and conditions of Cidara's 2020 Inducement Incentive Plan and its standard forms of grant agreements thereunder.

Cidara Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Cidara Therapeutics to Present Preclinical Data on CD388 at ASM Microbe 2024 Conference

SAN DIEGO, May 30, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, today announced the company will be presenting a poster at the American Society for Microbiology (ASM) Microbe 2024 conference to be held June 13-17, 2024 at the Georgia World Congress Center in Atlanta, Georgia.

Cidara Therapeutics to Present Preclinical Data on CD388 at ASM Microbe 2024 Conference

Cidara Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results

SAN DIEGO, May 15, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX) (the Company), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, today reported financial results for the first quarter ended March 31, 2024, and provided an update on its corporate activities and product pipeline.

Cidara Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results

Cidara Therapeutics Regains Compliance with Nasdaq Continued Listing Rules

SAN DIEGO, May 15, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, today announced that on May 14, 2024 it received a letter from the Listing Qualifications Department staff (the Staff) of the Nasdaq Stock Market LLC (Nasdaq) notifying the Company that it has regained compliance with Nasdaq's requirements for continued listing. In addition, the Nasdaq Hearing Panel (the Panel) imposed a discretionary Panel monitor until May 14, 2025, such that if the Company fails to maintain compliance with any continued listing requirement during such period, the Staff will issue a delist determination letter and the Company will promptly schedule a new hearing before the Panel to address such noncompliance.

Cidara Therapeutics Regains Compliance with Nasdaq Continued Listing Rules

CDTX INVESTOR NOTICE: ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Cidara Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation - CDTX

NEW YORK, May 10, 2024 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Cidara Therapeutics, Inc. (NASDAQ: CDTX) resulting from allegations that Cidara Therapeutics may have issued materially misleading business information to the investing public. SO WHAT: If you purchased Cidara Therapeutics securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

CDTX INVESTOR NOTICE: ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Cidara Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation - CDTX

Cidara Therapeutics: Now Well-Funded To Advance Its Cloudbreak Platform

Cidara Therapeutics, Inc. passed rezafungin rights to Mundipharma allowing reallocation of resources to the oncology Cloudbreak platform. Following a considerable private placement and re-acquisition of CD388 from Janssen, CDTX is well funded to start and complete a ph2b trial. Cidara Therapeutics no longer expects any milestone/royalty revenue but will be able to raise funds from a much stronger position following a positive ph2b trial for CD388.

Cidara Therapeutics: Now Well-Funded To Advance Its Cloudbreak Platform

See News Rankings